Table 3.

Hazard ratios for the association of baseline microalbuminuria (30–299 mg/g creatinine) and macroalbuminuria (>299 mg/g creatinine) with incident hip and pelvic fractures among ONTARGET and TRANSCEND participants without a history of hip or pelvic fractures

VariablesM1: HR (95% CI)M2: HR (95% CI)M3: HR (95% CI)
BL micro versus normal1.52 (1.10–2.09), P=0.011.36 (0.99–1.87), P=0.061.27 (0.910–1.76), P=0.16
BL macro versus normal2.01 (1.21–3.35), P=0.0072.02 (1.21–3.37), P=0.0071.71 (1.007–2.91), P=0.05
  • All other results are similar to Table 2. ONTARGET, Ongoing Telmisartan Alone and in combination with Ramipril Global End Point Trial; TRANSCEND, Telmisartan Randomized Assessment Study in Angiotensin-Converting Enzyme Intolerant Subjects with Cardiovascular Disease; M, model; HR, hazard ration; CI, confidence interval; BL, baseline.